Scholar Rock Q1 Earnings Call Highlights
3 Beaten-Down Stocks With Rebound Potential This Earnings SeasonScholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for children and ad
3 Beaten-Down Stocks With Rebound Potential This Earnings SeasonScholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for children and ad